Showing 2581-2590 of 3315 results for "".
- Outlook Therapeutics Provides Update on Type A Meetings with FDA for Wet AMD Product Candidatehttps://modernod.com/news/outlook-therapeutics-provides-update-on-type-a-meetings-with-fda-for-wet-amd-product-candidate/2481959/Outlook Therapeutics announced that it has completed the requested Type A Meetings with the FDA to discuss the complete response letter (CRL) dated August 29, 2023 regarding the biologics license application (BLA) for ONS-5010, an investigational ophthalmi
- World’s First Whole Eye & Partial Face Transplant Performed at NYU Langone Healthhttps://modernod.com/news/worlds-first-whole-eye-partial-face-transplant-performed-at-nyu-langone-health/2481958/A surgical team from NYU Langone Health performed the world’s first whole-eye and partial-face transplant for a 46-year-old military veteran from Arkansas who survived a work-related high-voltage electrical accident. The surgery included transplanting the entire left eye and a portion of th
- Alcon Canada Launches Clareon Vivity, its Latest Advancement in Presbyopia Correcting IOLshttps://modernod.com/news/alcon-canada-launches-clareon-vivity-its-latest-advancement-in-presbyopia-correcting-iols/2481956/Alcon announced that Clareon Vivity, the first and only non-diffractive extended depth of focus (EDOF) IOL on Alcon’s lens platform, is now available in Canada. [1-6] Clareon Vivity is designed to provide high-quality vision from distance to functional near with a visual dist
- IRIS Registry-based Study Evaluates Side-Effect of Semaglutide Weight-Loss Drug on Diabetic Retinopathyhttps://modernod.com/news/iris-registry-based-study-evaluates-side-effect-of-semaglutide-weight-loss-drug-on-diabetic-retinopathy/2481947/According to the American Academy of Ophthalmology (AAO), new review of real-world data offers reassurance for the use of the diabetes drug semaglutide, which is popular for helping people lower their glucose levels and better manage their weight. At issue has been that a potential side effect of
- Study of Sickle Retinopathy in Children Shows Similar Rate of Occurence as Adultshttps://modernod.com/news/study-of-sickle-retinopathy-in-children-shows-similar-rate-of-occurence-as-adults/2481945/The American Academy of Ophthalmology (AAO) announced the presentations of a study of sickle retinopathy, an age-dependent process that can develop in patients with sickle cell disease, of whom older patients are at substantially higher risk than younger patients. To learn more about ho
- Adverum’s Ixo-Vec for Wet AMD Evaluated in 3-Year Data from OPTIC Extension Studyhttps://modernod.com/news/adverums-ixo-vec-for-wet-amd-evaluated-in-3-year-data-from-optic-extension-study/2481951/Adverum Biotechnologies announced updated data from the OPTIC extension study of patients with wet age-related macular degeneration (AMD) and a summary of previously announced aflibercept protein levels from the LUNA study were presented during the Retina Subspecialty Day at AAO 2023 in
- AffaMed Therapeutics Announces Positive Topline Results from Real-World Study in China Evaluating Dextenza in Patients after Cataract Surgeryhttps://modernod.com/news/affamed-therapeutics-announces-positive-topline-results-from-real-world-study-in-china-evaluating-dextenza-in-patients-after-cataract-surgery/2481932/AffaMed Therapeutics announced positive topline results from the real-world study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain followi
- Alcon Showcases Cloud-Based Planning and Digital Technologies During AAO 2023https://modernod.com/news/alcon-showcases-cloud-based-planning-and-digital-technologies-during-aao-2023/2481930/At the upcoming American Academy of Ophthalmology (AAO) 2023 annual meeting in San Francisco, Alcon will provide connected equipment ecosystems via its digital innovation technology. Ophthalmologists, surgical staff, researchers, and industry leaders will have the opportunity to ex
- FDA Approves OnPoint Vision’s IDE Application to Begin Phase 1 of IOPCL Magnifierhttps://modernod.com/news/fda-approves-onpoint-visions-ide-application-to-begin-phase-1-of-iopcl-magnifier/2481925/OnPoint Vision announced the FDA approval of their investigational device exemption (IDE) application to begin phase 1 of their pivotal clinical trial of the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with
- ViaLase Completes Enrollment for the VIA-002 Trial of the ViaLase Laser to Treat Primary Open Angle Glaucomahttps://modernod.com/news/vialase-completes-enrollment-for-the-via-002-trial-of-the-vialase-laser-to-treat-primary-open-angle-glaucoma/2481921/ViaLase announced it has completed enrollment of VIA-002, the company's pivotal trial of the ViaLase Laser to treat adult patients with primary open angle glaucoma (POAG). The ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image